Table 1.
Clinical trials and reports exploring the use of CPIs in STS.
| Year Reported | Study | Intervention | Evaluable STS Patients (n) | ORR | Subtype Specific Objective Responses | Other Responses | ||
|---|---|---|---|---|---|---|---|---|
| UPS (n) | LMS (n) | DDLPS (n) | ||||||
| 2013 Maki [13] |
MSKCC Synovial Sarcoma pilot | Ipilimumab | 6 | 0% | NA | NA | NA | 0/6 SS |
| 2017 Ben Ami [14] |
Dana Farber uterine LMS phase II | Nivolumab | 12 | 0% | NA | 0/12 | NA | |
| 2015 Patnaik [15] |
KEYNOTE-001 | Pembrolizumab | 1 | 0% | NA | 0/1 | NA | |
| 2017 Groisberg [26] |
MD Anderson series | CPIs in various combos | 40 | 5% | 0/1 | 0/12 | 0/6 | |
| 2017 Tawbi [16] |
SARC028 | Pembrolizumab | 40 | 18% | 4/10 | 0/10 | 2/10 | 1/10 SS |
| 2019 Burgess [17] |
SARC028 expansion cohort | Pembrolizumab | 79 | 16% | 9/40 | NA | 4/39 | |
| 2018 D’Angelo [18] |
ALLIANCE A091401 | Nivolumab | 37 | 5% | 0/5 | 1/15 | 0/3 | 1/1 ASPS |
| 2018 D’Angelo [18] |
ALLIANCE A091401 | Nivolumab and ipilimumab | 37 | 16% | 2/6 1/6 unconfirmed |
2/14 | 0/2 | 1/1 MFS 1/3 AS |
| 2020 Chen [19] |
GIST/DDLPS/UPS expansions of ALLIANCE | Nivolumab | 36 | 6% | 1/12 | NA | 1/12 | 0/9 GIST |
| 2020 Chen [19] |
GIST/DDLPS/UPS expansions of ALLIANCE | Nivolumab and ipilimumab | 36 | 11% | 2/12 | NA | 2/12 | 0/9 GIST |
| 2020 Quiroga [20] |
Ohio State series | Nivolumab or pembrolizumab | 25 | 12% | 0/3 | 0/5 | 1/6 | 1 inflammatory myofibroblastic sarcoma |
| 2020 Somaiah [21] |
MD Anderson phase II | Durvalumab and tremelimumab | 57 | 14% | 1/5 | 0/5 | 0/6 | 5/10 ASPS 1/5 Chordoma 1/5 AS |
| 2020 Monga [22] |
US multi-institute | PD1 +/− CTLA4 or other CPIs (inc. anti-CSF1R) | 88 | 24% | 8/25 | 9/20 | NR | 1 fibroblastic sarcoma 1 SEF 1 MFS |
| 2020 Zhou [23] |
Stanford series | Nivolumab and ipilimumab | 38 | 15% | 1/8 (classed as sarcoma NOS) | 0/9 | 1/6 | 2/5 MFS 1/2 SFT 1/3 MPNST |
| 2021 Chen [24] |
Chinese multi-institute | Nivolumab | 76 | 7% | NR | NR | NR | |
| 2021 Chen [24] |
Chinese multi-institute | Nivolumab and ipilimumab | 74 | 13% | NR | NR | NR | |
| 2020 Italiano [8] |
Pooled analysis of phase II data | PD1/PDL1 +/− other CPIs | 384 | 15% | 16/103 | 5/82 | 4/61 | |
Abbreviations: AS, angiosarcoma; ASPS, alveolar soft part sarcoma; CPI, checkpoint inhibitor; DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumour; LMS, leiomyosarcoma; MFS, myxofibrosarcoma; MPNST, malignant peripheral nerve-sheath tumour; NA, not applicable; NOS, not otherwise specified; NR, not recorded; ORR, objective response rate; SEF, sclerosing epithelioid fibrosarcoma; SFT, solitary fibrous tumour; SS, synovial sarcoma; STS, soft tissue sarcoma; UPS, undifferentiated pleomorphic sarcoma.